home / stock / lbps / lbps quote
Last: | $1.65 |
---|---|
Change Percent: | 2.48% |
Open: | $1.61 |
Close: | $1.65 |
High: | $1.65 |
Low: | $1.61 |
Volume: | 3,914 |
Last Trade Date Time: | 06/24/2022 04:38:34 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.65 | $1.61 | $1.65 | $1.65 | $1.61 | 3,914 | 06-24-2022 |
$1.61 | $1.56 | $1.61 | $1.61 | $1.54 | 21,703 | 06-23-2022 |
$1.56 | $1.52 | $1.56 | $1.56 | $1.5 | 63,190 | 06-22-2022 |
$1.76 | $2.05 | $1.76 | $2.05 | $1.69 | 121,734 | 06-21-2022 |
$2.42 | $2.35 | $2.42 | $2.46 | $2.34 | 2,380 | 06-20-2022 |
$2.42 | $2.35 | $2.42 | $2.46 | $2.34 | 2,380 | 06-17-2022 |
$2.3499 | $2.34 | $2.3499 | $2.3499 | $2.29 | 2,660 | 06-16-2022 |
$2.4201 | $2.44 | $2.4201 | $2.535 | $2.4201 | 2,704 | 06-15-2022 |
$2.4371 | $2.5 | $2.4371 | $2.65 | $2.41 | 4,794 | 06-14-2022 |
$2.54 | $2.45 | $2.54 | $2.59 | $2.45 | 5,393 | 06-13-2022 |
$2.67 | $2.75 | $2.67 | $2.75 | $2.56 | 10,717 | 06-10-2022 |
$2.7744 | $2.95 | $2.7744 | $3.03 | $2.7744 | 13,395 | 06-09-2022 |
$3.0331 | $3 | $3.0331 | $3.15 | $2.95 | 17,475 | 06-08-2022 |
$3.21 | $3.09 | $3.21 | $3.33 | $3.0204 | 14,736 | 06-07-2022 |
$3.33 | $3.26 | $3.33 | $3.355 | $3.2453 | 7,847 | 06-06-2022 |
$3.3958 | $3.33 | $3.3958 | $3.3958 | $3.31 | 6,204 | 06-03-2022 |
$3.35 | $3.165 | $3.35 | $3.35 | $3.165 | 4,057 | 06-02-2022 |
$3.1064 | $3.25 | $3.1064 | $3.25 | $3.1 | 4,600 | 06-01-2022 |
$3.22 | $3.26 | $3.22 | $3.3 | $3.218 | 4,351 | 05-31-2022 |
$3.31 | $3.34 | $3.31 | $3.42 | $3.31 | 4,757 | 05-30-2022 |
News, Short Squeeze, Breakout and More Instantly...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (ȁ...
4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company’s request for a...
- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LB...